Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna M G Pasmooij

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Investigation|May 4, 2007
Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3Anna M G Pasmooij, Hendri H Pas, Maria C Bolling, et al.
Drug Discovery Today|May 28, 2025
Insights from the European Medicines Agency on digital health technology derived endpointsKeerti D Jadoenathmisier, Helga Gardarsdottir, Peter G M Mol, et al.
Clinical Pharmacology and Therapeutics|May 7, 2026
Artificial Intelligence for Regulatory Evidence: A Systematic Document Analysis of European Medicines Agency Regulatory Advice and Public ReportsLucina-May Nollen, Gerard J P van Westen, Gabriel Westman, et al.
Drug Discovery Today|June 21, 2020
Breakthrough therapy-designated oncology drugs: are they rightfully criticized?Jorn Mulder, Anna M G Pasmooij, Violeta V Stoyanova-Beninska, et al.
Expert Review of Molecular Diagnostics|June 8, 2022
Impact of the new European Union <i>In Vitro</i> Diagnostics Regulation on the practice of hospital diagnostic laboratoriesAudrey M M Hermans, Marc Maliepaard, Wouter P C Boon, et al.
Clinical Pharmacology and Therapeutics|April 29, 2024
The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country ReportAnna M G Pasmooij, Peter G M Mol, Jacob Cornelis Bot, et al.
American Journal of Human Genetics|October 28, 2005
Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosaAnna M G Pasmooij, Hendri H Pas, Franciska C L Deviaene, et al.
Drug Discovery Today|October 20, 2024
Environmental risk assessment in the EU regulation of medicines for human use: an analysis of stakeholder perspectives on its current and future roleJim F Zinken, Anna M G Pasmooij, Antwan G H Ederveen, et al.
Experimental Dermatology|December 17, 2013
Pigmentation and melanocyte supply to the epidermis depend on type XVII collagenAntoni Gostyński, Anna M G Pasmooij, Marcela Del Rio, et al.
JAMA Dermatology|July 8, 2016
Association of Epidermolysis Bullosa Simplex With Mottled Pigmentation and EXPH5 MutationsIana Turcan, Anna M G Pasmooij, Peter C Van den Akker, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Investigation|May 4, 2007
Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3Anna M G Pasmooij, Hendri H Pas, Maria C Bolling, et al.
Drug Discovery Today|May 28, 2025
Insights from the European Medicines Agency on digital health technology derived endpointsKeerti D Jadoenathmisier, Helga Gardarsdottir, Peter G M Mol, et al.
Clinical Pharmacology and Therapeutics|May 7, 2026
Artificial Intelligence for Regulatory Evidence: A Systematic Document Analysis of European Medicines Agency Regulatory Advice and Public ReportsLucina-May Nollen, Gerard J P van Westen, Gabriel Westman, et al.
Drug Discovery Today|June 21, 2020
Breakthrough therapy-designated oncology drugs: are they rightfully criticized?Jorn Mulder, Anna M G Pasmooij, Violeta V Stoyanova-Beninska, et al.
Expert Review of Molecular Diagnostics|June 8, 2022
Impact of the new European Union <i>In Vitro</i> Diagnostics Regulation on the practice of hospital diagnostic laboratoriesAudrey M M Hermans, Marc Maliepaard, Wouter P C Boon, et al.
Clinical Pharmacology and Therapeutics|April 29, 2024
The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country ReportAnna M G Pasmooij, Peter G M Mol, Jacob Cornelis Bot, et al.
American Journal of Human Genetics|October 28, 2005
Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosaAnna M G Pasmooij, Hendri H Pas, Franciska C L Deviaene, et al.
Drug Discovery Today|October 20, 2024
Environmental risk assessment in the EU regulation of medicines for human use: an analysis of stakeholder perspectives on its current and future roleJim F Zinken, Anna M G Pasmooij, Antwan G H Ederveen, et al.
Experimental Dermatology|December 17, 2013
Pigmentation and melanocyte supply to the epidermis depend on type XVII collagenAntoni Gostyński, Anna M G Pasmooij, Marcela Del Rio, et al.
JAMA Dermatology|July 8, 2016
Association of Epidermolysis Bullosa Simplex With Mottled Pigmentation and EXPH5 MutationsIana Turcan, Anna M G Pasmooij, Peter C Van den Akker, et al.
Pageof 6